|
Age at transplantation (years) (mean ± SD, range)
|
52.5 ± 13 (19–81)
|
54.1 ± 12 (24–76)
|
0.22
|
|
Sex (N, %)
| | |
0.42
|
|
Male
|
144 (62)
|
119 (58)
| |
|
Female
|
89 (38)
|
86 (42)
| |
|
Donor Source (N, %)
| | |
0.002
|
|
Deceased
|
142 (61)
|
154 (75)
| |
|
Live
|
91 (39)
|
51 (25)
| |
|
Number of transplants
| | |
0.4
|
|
One
|
224 (97)
|
194 (96)
| |
|
Two
|
7 (3)
|
9 (4)
| |
|
Cause of end-stage kidney disease (N, %)
|
|
Diabetes
|
41 (18)
|
44 (22)
|
0.30
|
|
Hypertension
|
25 (11)
|
19 (9)
|
0.61
|
|
Glomerulonephritis
|
94 (40)
|
78 (38)
|
0.62
|
|
Polycystic kidney disease
|
23 (10)
|
28 (14)
|
0.21
|
|
Congenital kidney disease
|
10 (4)
|
7 (3)
|
0.63
|
|
Others
|
40 (17)
|
29 (14)
|
0.28
|
|
Ethnicity
|
|
Caucasian
|
94 (40)
|
70 (34)
|
0.13
|
|
Black
|
16 (7)
|
21 (10)
|
0.20
|
|
East Asian
|
32 (14)
|
20 (10)
|
0.19
|
|
South Asian
|
47 (20)
|
53 (26)
|
0.15
|
|
Other
|
43 (19)
|
41 (20)
|
0.71
|
|
Pre-transplant dialysis modality (N, %)
| | |
0.015
|
|
Hemodialysis
|
122 (53)
|
131 (64)
| |
|
Peritoneal dialysis
|
69 (30)
|
54 (27)
| |
|
Preemptive
|
36 (17)
|
18 (9)
| |
|
Dialysis duration (days) (mean ± SD)
|
1790 ± 1315
|
2052 ± 1427
|
0.06
|
|
Cytomegalovirus IgG antibody N (%)
|
174 (75)
|
167 (81)
|
0.18
|
|
Epstein Barr virus IgG antibody N (%)
|
211 (91)
|
189 (93)
|
0.70
|
|
Hepatitis B surface antigen N (%)
|
4 (2)
|
3 (1)
|
0.29
|
|
Hepatitis C antibody N (%)
|
4 (2)
|
2 (1)
|
0.41
|
|
HIV antibody N (%)
|
2 (1)
|
4 (2)
|
0.29
|
|
Tuberculin skin test positive N (%)
|
31 (13)
|
11 (5)
|
0.33
|
|
Cumulative Panel Reactive Antibody (%)(mean ± SD, range)
|
7.5 ± 20 (0–99)
|
13.5 ± 28 (0–100)
|
0.02
|
|
History of smoking (N, %)
|
94 (42)
|
56 (28)
|
0.003
|
|
Delayed graft function N (%)
|
38 (16)
|
41 (20)
|
0.31
|
|
Acute rejection N (%)
|
7 (3)
|
18 (9)
|
0.009
|
|
Post-transplant diabetes (N, %)
|
19 (8)
|
16 (8)
|
0.81
|
|
Graft loss N (%)
|
2 (1)
|
0 (0)
|
0.28
|
|
Immunosuppressive medication at discharge (N, %)
|
|
Tacrolimus
|
215 (93)
|
189 (93)
|
0.99
|
|
Cyclosporine
|
11 (5)
|
14 (7)
|
0.34
|
|
Mycophenolate mofetil
|
104 (45)
|
80 (39)
|
0.23
|
|
or mycophenolic acid
|
103 (45)
|
95 (44)
|
0.64
|
|
Azathioprine
|
11 (5)
|
4 (2)
|
0.09
|
|
Prednisone
|
219 (95)
|
196 (97)
|
0.37
|
|
Other medication (N, %)
|
|
Angiotensin-converting enzyme inhibitor
|
12 (5)
|
9 (4)
|
0.71
|
|
Angiotensin II receptor blocker
|
19 (8)
|
24 (12)
|
0.21
|
|
Non-dihydropyridine calcium channel blocker
|
21 (9)
|
13 (6)
|
0.28
|
|
Dihydropyridine calcium channel blocker
|
100 (43)
|
100 (49)
|
0.21
|
|
Beta blocker
|
87 (37)
|
90 (44)
|
0.15
|
|
Alpha blocker
|
23 (10)
|
19 (9)
|
0.83
|
|
Loop diuretic
|
10 (4)
|
12 (6)
|
0.29
|
|
Thiazide diuretic
|
4 (2)
|
4 (2)
|
0.56
|
